Citius Pharmaceuticals, Inc. Operating Lease Cost
Citius Pharmaceuticals, Inc. (CTXR) reported Operating Lease Cost of $144.25 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2026-06-30 was $91.87K, a 30.82% increase year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2026-03-31 was $16.32K, a 72.66% decline year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2025-12-31 was $36.05K, a 39.62% decline year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2025-09-30 was $79.50K, a 33.16% increase year-over-year.
- Citius Pharmaceuticals, Inc. operating lease, cost for fiscal 2025 was $269.14K, a 12.70% increase from fiscal 2024.
- Citius Pharmaceuticals, Inc. operating lease, cost for fiscal 2024 was $238.82K, a 0.00% decline from fiscal 2023.
- Citius Pharmaceuticals, Inc. operating lease, cost for fiscal 2023 was $238.82K, a 0.00% increase from fiscal 2022.
- Citius Pharmaceuticals, Inc. operating lease, cost for fiscal 2022 was $238.82K, a 0.00% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $91.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $108.20K derived: sum of 2 quarters · filed 2026-08-14 | $144.25K 10-Q · filed 2026-08-14 | $223.75K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $16.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $52.38K 10-Q · filed 2026-05-15 | $131.88K derived: sum of 3 quarters · filed 2026-05-15 | $202.11K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $36.05K 10-Q · filed 2026-02-13 | $115.55K derived: sum of 2 quarters · filed 2026-02-13 | $185.78K derived: sum of 3 quarters · filed 2026-08-14 | $245.49K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-09-30 | $79.50K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $149.73K derived: sum of 2 quarters · filed 2026-08-14 | $209.44K derived: sum of 3 quarters · filed 2026-08-14 | $269.14K 10-K · filed 2025-12-23 | |
| 2025-06-30 | $70.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $129.94K derived: sum of 2 quarters · filed 2026-08-14 | $189.64K 10-Q · filed 2026-08-14 | $249.35K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $59.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $119.41K 10-Q · filed 2026-05-15 | $179.12K derived: sum of 3 quarters · filed 2026-05-15 | $238.82K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $59.70K 10-Q · filed 2026-02-13 | $119.41K derived: sum of 2 quarters · filed 2026-02-13 | $179.12K derived: sum of 3 quarters · filed 2026-02-13 | $238.82K derived: sum of 4 quarters · filed 2026-02-13 | |
| 2024-09-30 | $59.71K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $119.41K derived: sum of 2 quarters · filed 2025-12-23 | $179.12K derived: sum of 3 quarters · filed 2025-12-23 | $238.82K 10-K · filed 2025-12-23 | |
| 2024-06-30 | $59.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $119.41K derived: sum of 2 quarters · filed 2025-08-12 | $179.12K 10-Q · filed 2025-08-12 | $238.82K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $59.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $119.41K 10-Q · filed 2025-05-14 | $179.12K derived: sum of 3 quarters · filed 2025-05-14 | $179.12K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $59.70K 10-Q · filed 2025-02-14 | $119.41K derived: sum of 2 quarters · filed 2025-02-14 | $119.41K derived: sum of 3 quarters · filed 2025-02-14 | $238.82K derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $59.71K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $59.71K derived: sum of 2 quarters · filed 2024-12-27 | $179.12K derived: sum of 3 quarters · filed 2024-12-27 | $238.82K 10-K · filed 2024-12-27 | |
| 2023-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | $119.41K derived: sum of 2 quarters · filed 2024-08-12 | $179.12K 10-Q · filed 2023-08-14 | $238.82K derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $119.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $179.12K 10-Q · filed 2024-08-12 | $119.41K 10-Q · filed 2023-05-12 | $238.82K derived: sum of 3 quarters · filed 2024-08-12 | $298.53K derived: sum of 4 quarters · filed 2024-08-12 |
| 2022-12-31 | $59.71K 10-Q · filed 2024-02-14 | $119.41K derived: sum of 2 quarters · filed 2024-02-14 | $179.12K derived: sum of 3 quarters · filed 2024-02-14 | $238.82K derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-09-30 | $59.71K derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | $119.41K derived: sum of 2 quarters · filed 2023-12-29 | $179.12K derived: sum of 3 quarters · filed 2023-12-29 | $238.82K 10-K · filed 2023-12-29 | |
| 2022-06-30 | $59.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | $119.41K derived: sum of 2 quarters · filed 2023-08-14 | $179.12K 10-Q · filed 2023-08-14 | $238.82K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $59.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | $119.41K 10-Q · filed 2023-05-12 | $179.12K derived: sum of 3 quarters · filed 2023-05-12 | $238.82K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $59.70K 10-Q · filed 2023-02-10 | $119.41K derived: sum of 2 quarters · filed 2023-02-10 | $179.12K derived: sum of 3 quarters · filed 2023-02-10 | $238.82K derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | $59.71K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | $119.41K derived: sum of 2 quarters · filed 2022-12-22 | $179.12K derived: sum of 3 quarters · filed 2022-12-22 | $238.82K 10-K · filed 2022-12-22 | |
| 2021-06-30 | $59.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | $119.41K derived: sum of 2 quarters · filed 2022-08-11 | $179.12K 10-Q · filed 2022-08-11 | $240.22K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $59.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-12 | $119.41K 10-Q · filed 2022-05-12 | $180.51K derived: sum of 3 quarters · filed 2022-05-12 | $221.40K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $59.71K 10-Q · filed 2022-02-10 | $120.81K derived: sum of 2 quarters · filed 2022-02-10 | $161.69K derived: sum of 3 quarters · filed 2022-02-10 | $231.19K derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-09-30 | $61.10K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15 | $101.98K derived: sum of 2 quarters · filed 2021-12-15 | $171.48K derived: sum of 3 quarters · filed 2021-12-15 | $228.83K 10-K · filed 2021-12-15 | |
| 2020-06-30 | $40.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $110.38K derived: sum of 2 quarters · filed 2021-08-12 | $167.72K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $69.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-13 | $126.84K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $57.35K 10-Q · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |